Genotype and Subtype Mapping of the Hepatitis C Virus
Key facts
- Where
- Créteil, FranceSee the site
Where in France
- AP-HP Henri MondorCréteil, FranceContact: Laetitia GREGOIRENo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07503288
- Record updated
- 19 May 2026
- Original description
Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC).Read full original descriptionShow less
Cartographie Des génotypes et Sous-types du Virus de l'hépatite C
Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC).
The CARTO-VHC study is a retrospective, observational, multicenter study based on data and samples collected during routine care from 2023 to 2024. The study does not involve direct human participation. The study aims to describe the different genotypes and subtypes of the hepatitis C virus, including unusual subtypes, in a large population of newly diagnosed HCV-positive patients. This will help identify the most common types circulating in France. Additionally, the study will provide a comprehensive understanding of therapeutic failures and drug resistance to direct-acting antivirals (DAA) in treated patients.
Inclusion: Patient aged 18 years old or more; Newly diagnosed patient positive for HCV (presence of HCV antibodies); Patient with active infection (HCV RNA > 0).
Exclusion: Patients who decline to participate in the study and oppose the use of their personal data; Patients under legal protection (guardianship or curatorship).